Diabetes dataset for AI training, LLM diabetes training data, machine learning dataset
Pathophysiology of diabetes, including hormone roles, glucose transporters, mechanisms of Type 2 diabetes (T2DM), and causes of other diabetes forms
{
“Pathophysiology_of_Diabetes”: {
“Hormonal_Regulation”: {
“Primary_Hormones”: {
“Insulin”: {
“Source”: “β cells of pancreas”,
“Function”: [
“Inhibits glucose production via glycogenolysis and gluconeogenesis”,
“Increases glucose uptake in liver, muscle, and fat”
]
},
“Glucagon”: {
“Source”: “α cells of pancreas”,
“Function”: [
“Antagonizes insulin”,
“Promotes glycogenolysis and gluconeogenesis”
],
“Other_Hormones”: [“Cortisol”, “Catecholamines”]
}
},
“Additional_Hormones”: {
“Amylin”: {
“Type”: “Peptide hormone (37 amino acids)”,
“Function”: “Decreases gastric emptying, enhances glucose absorption”
},
“GLP-1”: {
“Type”: “Incretin (30 amino acids)”,
“Function”: “Enhances insulin synthesis and secretion”
},
“GIP”: {
“Type”: “Incretin (42 amino acids)”,
“Function”: “Stimulates insulin secretion”
}
}
},
“Glucose_Transporters”: {
“Types”: [
“Sodium glucose co-transporter (SGLT)”,
“Facilitative glucose transporter (GLUT)”
],
“Function”: “Facilitates absorption and cellular uptake of glucose”
},
“Diabetes_Types”: {
“Type_1_DM”: {
“Cause”: “Autoimmune destruction of β cells”,
“Notes”: “Genetic predisposition involved”
},
“Type_2_DM”: {
“Cause”: “Combination of genetic and lifestyle factors”,
“Risk_Factors”: [“Obesity”, “Sedentary lifestyle”],
“Ominous_Octet”: [
“Reduced insulin secretion from β cells”,
“Elevated glucagon secretion from α cells”,
“Increased hepatic glucose production”,
“Neurotransmitter dysfunction and insulin resistance in brain”,
“Increased lipolysis”,
“Increased renal glucose reabsorption”,
“Reduced incretin effect”,
“Decreased peripheral glucose uptake (muscle, liver, adipose tissue)”
]
},
“Gestational_Diabetes”: {
“Cause”: “Placental hormones cause insulin resistance during pregnancy”
},
“Monogenic_Diabetes”: {
“Subtypes”: [“Neonatal diabetes”, “MODY”],
“Cause”: “Single gene mutation”
},
“Secondary_Diabetes”: {
“Cystic_Fibrosis”: “Pancreatic scarring leads to impaired insulin production”,
“Hemochromatosis”: “Iron overload damages pancreas”,
“Hormonal_Diseases”: {
“Cushing_Syndrome”: “Excess cortisol production”,
“Acromegaly”: “Excess growth hormone”,
“Hyperthyroidism”: “Excess thyroid hormone”
},
“Pancreatic_Damage”: [
“Pancreatitis”,
“Pancreatic cancer”,
“Trauma or surgical removal”
],
“Drug_Induced_Diabetes”: [
“Niacin”,
“Certain diuretics”,
“Anti-seizure drugs”,
“Psychiatric drugs”,
“HIV medications”,
“Pentamidine”,
“Glucocorticoids”,
“Immunosuppressants”,
“Statins”
]
}
}
}
}
Alpha Glucosidase Inhibitors + DPP-IV Inhibitors + Combination Studies
Sample Code for
[
{
“drug_class”: “DPP-IV Inhibitor + AGI”,
“study_description”: “Linagliptin tested alone or in combination with voglibose or exendin-4 to evaluate glycemic control in T2DM patients.”,
“outcome”: “Linagliptin + voglibose significantly reduced body weight, improved glycemic control, and lowered plasma insulin. Linagliptin + exendin-4 showed no effect on plasma GLP-1. Combination of linagliptin and voglibose was superior to individual drugs.”,
},
{
“drug_class”: “DPP-IV Inhibitor vs AGI”,
“study_description”: “Comparison of Linagliptin vs Voglibose monotherapy for postprandial glucose control.”,
“outcome”: “Linagliptin lowered fasting glucose and HbA1c, but had limited effect on postprandial glucose. It was preferred for fewer side effects and low hypoglycemia incidence.”,
},
{
“drug_class”: “GIP/GLP-1 Dual Agonist”,
“study_description”: “Study on unimolecular dual GIP/GLP-1 agonist NNC0090-2746 for T2DM therapy.”,
“outcome”: “Dual agonist NNC0090-2746 significantly reduced HbA1c, body weight, and total cholesterol, showing synergistic effects.”,
},
{
“drug_class”: “Triple Therapy – AGI + Metformin + Sulfonylurea”,
“study_description”: “Comparison of dual therapy (Metformin + Glimepiride) vs triple therapy (Voglibose + Metformin + Glimepiride) in T2DM patients.”,
“outcome”: “Triple therapy provided better control over FBS, PPBS, HbA1c, and BMI. Showed kidney protection and improved lipid profile, with no change in blood urea.”,
},
{
“drug_class”: “Dual Therapy – AGI or Metformin + Insulin”,
“study_description”: “Comparison of dual therapies: Metformin + Insulin vs Voglibose + Insulin.”,
“outcome”: “Voglibose + Insulin group showed better therapeutic efficacy in FBS, PPBS, RBS, and HbA1c.”,
Different reports on novel drug delivery of antidiabetic drug delivery for T2DM
Looking for a more dataset write to us : ieearctechnologies@gmail.com
Download the zip file
For more updates, follow WhatsApp channel